$PODD

WEATHERMAN ELIZABETH H purchased $497K of PODD

WEATHERMAN ELIZABETH H purchased 3,450 shares of INSULET CORP (PODD) at $144.20 ($0.50M total) on 2026-06-03.

Original reporting
SEC EDGAR · WEATHERMAN ELIZABETH H
Published Jun 3, 2026, 8:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 3, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PODD
Bullish
medium confidence
Mentioned
$PODD
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PODDBullishLow
01

Why it matters

Traders may treat it as a sentiment input, but without accompanying earnings/guidance/contract updates it usually won’t drive a durable repricing.

02

Market read

A disclosed director open-market buy can slightly support sentiment, but it lacks fundamental new information.

03

What to watch

No 10b5-1 plan is cited, but the article also doesn’t indicate whether this is part of a series of buys/sells or driven by pre-existing compensation/option exercises.

Relevance 6/10Novelty 8/10Timing: today’s SEC Form 4 disclosure (2026-06-03)

Background

The article is an SEC Form 4 insider transaction disclosure for Insulet’s director.

Company-level read

Ticker impact

$PODDBullishMedium confidence
Context

Insider director Elizabeth H. Weather-man purchased 3,450 shares of Insulet (PODD) on 2026-06-03 at $144.20/share via open-market transaction.

Expected impact

Likely limited near-term impact; any effect is typically small and short-lived unless part of a broader pattern.

Evidence & confidence

The filing is a disclosed ownership change (director buy) with a specific price and size, but no new company-specific operational or financial information is provided.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide driver.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine (liquidity needs, diversification, or non-informational timing) and may not reflect near-term fundamentals.

Key entities

  • Insulet Corp

    Subject of the SEC Form 4 insider purchase; director bought 3,450 shares at $144.20/share.

  • WEATHERMAN ELIZABETH H

    Director who executed the open-market purchase disclosed on 2026-06-03.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RMDMedAI 8/10

Patient Monitoring Stocks Q2 Teardown: ResMed (NYSE:RMD) Vs The Rest

ResMed (RMD) and peers reported Q2 earnings, with revenues beating estimates by 1.4% but next quarter's guidance below. RMD's revenue grew 8.6% YoY, meeting expectations, while iRhythm (IRTC) saw 20.1% growth, exceeding estimates. Insulet (PODD) and DexCom (DXCM) also reported, with mixed results. Stocks have declined since earnings, with RMD down 2.3% and IRTC down 13%.

$PODDMed

Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?

Insulet PODD reports strong growth in Omnipod 5 AID system adoption, with Q2 2026 revenues up 23.8%. The company faces competition and macroeconomic pressures but has raised international growth guidance. PODD's earnings beat estimates for four straight quarters, with a 22.2% long-term growth rate. Management expects continued expansion and product development, including Omnipod 6 and a Type 2 system launch in 2027.

$PODDMed

Is Class Action Scrutiny Of Omnipod Controls Altering The Investment Case For Insulet (PODD)?

Insulet (PODD) faces class action lawsuits alleging false statements about manufacturing controls and safety risks in its insulin delivery products. The lawsuits, filed by Robbins Geller and Rosen Law Firm, cover shares bought between February 2025 and May 2026. Insulet maintains revenue growth guidance of 21-23% for 2026 despite recent recalls affecting 7 million units. Analysts project varying revenue and earnings estimates for 2029, with growth potential but increased risks due to manufacturi

$PODDMedAI 8/10

Insulet (PODD) Q2 2026 Earnings Call Transcript

Insulet (PODD) reported Q2 2026 revenue of $801.7M, up 22.7% constant currency and above guidance. Adjusted EPS was $1.66, up 41.5%. U.S. Omnipod revenue was $544.1M, and international was $251.8M. Management revised U.S. full-year Omnipod growth to 17% to 19% and raised international to 30% to 32%, citing weaker type 2 retention.